Thomas Cavanagh – Chief Executive Officer
Thomas is a co-founder, the Chief Executive Officer and a Board member at Oxular Limited. Thomas is an experienced ophthalmic pharmaceutical industry executive with a significant product development and transaction track record. He was formerly co-founder and Chief Executive Officer of Aciex Therapeutics, where he brought its lead program to NDA, oversaw the development of a novel API technology which became the basis for future products and led a successful M&A exit. His prior professional history includes positions as both a company officer and a consultant where he worked in operational and advisory roles related to capital raises, M&A transactions, industry consolidations, strategic planning, debt financings and post-merger integration. Thomas has an MBA from the Kellogg School of Management and a BSc from Binghamton University.
Ronald Yamamoto – Chief Scientific Officer
Ronald is a co-founder, the Chief Scientific Officer and a Board member at Oxular Limited. Ronald has more than 30 years of medical device and drug product development experience. He has led multi-disciplinary technical teams, clinical trial development and product registration in the US, the EU, China and Brazil. His ophthalmic experience includes development of novel microcatheters for surgical treatment of glaucoma and retinal disease, sub-retinal access devices, diagnostic microspheres and drug-releasing implants. Ronald’s technical background is in chemical engineering, biomaterials engineering and biochemistry and he is the inventor on more than 40 granted patents related to medical products. Ronald has a BSc in Chemical Engineering from the California Institute of Technology and an MSc in Biomaterials Engineering from Clemson University and has completed additional postgraduate studies in Biochemistry at Clemson University and the University of Southern California.
Marc De Smet – Chief Medical Officer
Marc is the Chief Medical Officer of Oxular Limited and a practicing vitreoretinal surgeon. Marc has over 30 years of experience in ophthalmic drug and medical device development. Previously, Marc was the NEI/NIH representative responsible for defining the clinical trial of Foscarnet, the first approved drug to treat CMV retinitis in AIDS patients. He also initiated the use of Methotrexate for the treatment of intraocular lymphoma and intraocular tuberculosis. In collaboration with Thrombogenics, Marc was responsible for preclinical and clinical activities of Ocriplasmin, leading to the commercialization of Jetrea. Marc participated in the launch OTI’s transversal retinal OCT imaging and the development of Preceyes BV’s tele-operated robot dedicated to eye surgery. Marc holds a BSC (hon) from the University of Ottawa, MD from McGill University, and a PhD from the University of Amsterdam. Marc completed residency in Ophthalmology in UBC, Vancouver, a fellowship in Uveitis at the NEI, and a VR fellowship at Johns Hopkins. Marc also held posts a head of the clinical immunology department of the NEI/LI and department head of Ophthalmology at the University of Amsterdam.
Robert Waters – Vice President, Regulatory Affairs
Robert is Vice President, Regulatory Affairs at Oxular Limited. Robert has over 17 years of regulatory experience including an extensive history developing and registering drug products and devices in ophthalmology. Robert was previously Global Regulatory Lead for Urology and Ophthalmology at Astellas and worked at Allergan for nearly 10 years in various European regulatory roles including Head of Ophthalmology Regulatory and Head of Regulatory Development. At Allergan, Robert led teams responsible for obtaining drug product approvals in glaucoma and back-of-the-eye diseases including the European registration of OZURDEX™ for RVO, Uveitis and DME. Robert also spent five years at Bausch & Lomb where he gained early experience developing ophthalmic drug device combinations for the US and EU markets. Robert is a registered Pharmacist and holds a PhD in Analytical Chemistry from The School of Pharmacy, University of London.
Jane Bridgman – Vice President, Clinical Operations
Jane is Vice President, Clinical Operations at Oxular Limited. Jane brings more than 20 years’ clinical operations experience including an extensive background in ophthalmology. Jane was Director, Clinical Operations, Ophthalmology at Allergan where she served for more than 10 years in escalating roles of responsibility and lead multiple clinical programs for both ophthalmic drug and device products. Most recently, Jane was responsible for managing Allergan’s European Ophthalmology team as well as its Global Program Operations for a suite of large studies for Abicipar, Allergan’s late stage anti-VEGF therapy. Previously, Jane worked in various clinical operations roles in oncology, pediatrics, cardiology at Eli Lilly and Roche. Jane has a BSc (Hons) from the University of Wales, Cardiff.
Stacey Tucker – Chief Fiduciary
Stacey manages Oxular’s Finance and Administration providing objectivity and leadership as the Company’s chief fiduciary. Stacey has significant experience across the entire finance function including cash flow management and operational forecasting, accounting and reporting, tax reporting, financial audits, and R&D tax credits filings, general business transactions, human resources and oversight of general administration. Stacey has significant experience in supporting business financings and investor and board relations. Stacey also coordinates information technology and accounting systems, insurance programs, and technology grant applications. Stacey previously led finance teams in several industries including publishing and aviation where at Hangar8 she lead through a public listing in 2010 and reverse takeover with Gama Aviation in 2015. Stacey holds a BA (hons) in Accounting and Taxation from Bournemouth University and is also an ACCA qualified accountant.